Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
31.23
+0.02 (0.06%)
May 16, 2025, 4:00 PM - Market closed
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Crinetics Pharmaceuticals stock ranges from a low of $54 to a high of $97. The average analyst price target of $73.36 forecasts a 134.90% increase in the stock price over the next year.
Price Target: $73.36 (+134.90%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +92.12% | Mar 25, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $92 → $91 | Buy | Maintains | $92 → $91 | +191.39% | Feb 28, 2025 |
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Feb 4, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $55 | Hold → Strong Buy | Upgrades | $55 | +76.11% | Jan 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $81 | Strong Buy | Reiterates | $81 | +159.37% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
4.74M
from 1.04M
Increased by 356.40%
Revenue Next Year
37.95M
from 4.74M
Increased by 700.38%
EPS This Year
-4.18
from -3.69
EPS Next Year
-4.48
from -4.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 52.1M | 338.6M | ||
| Avg | 4.7M | 38.0M | 192.9M | ||
| Low | 1.4M | 24.6M | 95.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 910.6% | 998.3% | 792.2% | ||
| Avg | 356.4% | 700.4% | 408.2% | ||
| Low | 32.1% | 419.0% | 151.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.03 | -2.53 | -0.80 | ||
| Avg | -4.18 | -4.48 | -3.38 | ||
| Low | -5.00 | -6.05 | -5.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.